A Randomized Controlled Trial of Venlafaxine ER Versus Placebo in Pediatric Social Anxiety Disorder

Biological Psychiatry

Volumn 62, Issue 10, 2007, Pages 1149-1154

  March, John S ^a   Entusah, A Richard ^b   Rynn, Moira ^c   Albano, Anne Marie ^c   Tourian, Karen A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

adolescent; child; randomized controlled trial; social anxiety disorder; venlafaxine

Indexed keywords

PLACEBO; VENLAFAXINE;

ADOLESCENT; ANOREXIA; ARTICLE; ASTHENIA; AUTOMUTILATION; BEHAVIOR; BEHAVIOR DISORDER; CHILD PSYCHIATRY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERKINESIA; HYPERTENSION; HYPOMANIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYDRIASIS; NAUSEA; NERVOUSNESS; OUTPATIENT; PHARYNGITIS; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RESTLESSNESS; SCHOOL CHILD; SIDE EFFECT; SOCIAL PHOBIA; STATISTICAL SIGNIFICANCE; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; WEIGHT REDUCTION;

ADOLESCENT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CHILD; CONFIDENCE INTERVALS; CYCLOHEXANOLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PEDIATRICS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 34548854809     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.02.025     Document Type: Article

References (25)

1. Stein M.B., Fuetsch M., Muller N., Hofler M., Lieb R., and Wittchen H.U. Social anxiety disorder and the risk of depression: A prospective community study of adolescents and young adults. Arch Gen Psychiatry 58 (2001) 251-256
2. Ollendick T.H., and March J.S. Phobic and Anxiety Disorders: A Clinician's Guide to Effective Psychosocial and Pharmacological Interventions (2004), Oxford University Press, London
3. Stein D.J., Ipser J.C., and Balkom A.J. Pharmacotherapy for social phobia. Cochrane Database Syst Rev 4 (2004) CD001206
4. Liebowitz M.R., Gelenberg A.J., and Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 62 (2005) 190-198
5. Rickels K., Mangano R., and Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 24 (2004) 488-496
6. Compton S.N., Grant P.J., Chrisman A.K., Gammon P.J., Brown V.L., and March J.S. Sertraline in children and adolescents with social anxiety disorder: An open trial. J Am Acad Child Adolesc Psychiatry 40 (2001) 564-571
7. Birmaher B., Axelson D.A., Monk K., Kalas C., Clark D.B., Ehmann M., et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 42 (2003) 415-423
8. Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 344 (2001) 1279-1285
9. Wagner K.D., Berard R., Stein M.B., Wetherhold E., Carpenter D.J., Perera P., et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61 (2004) 1153-1162
10. Andrews J.M., Ninan P.T., and Nemeroff C.B. Venlafaxine: A novel antidepressant that has a dual mechanism of action. Depression 4 (1996) 48-56
11. Stahl S.M., Grady M.M., Moret C., and Briley M. SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10 (2005) 732-747
12. Weller E.B., Weller R.A., and Davis G.P. Use of venlafaxine in children and adolescents: A review of current literature. Depress Anxiety 12 suppl 1 (2000) 85-89
13. Whittington C.J., Kendall T., Fonagy P., Cottrell D., Cotgrove A., and Boddington E. Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet 363 9418 (2004) 1341-1345
14. Silverman W., and Albano A. The Anxiety Disorders Interview Schedule for DSM-IV, Child and Parent Versions (1996), The Psychological Corporation, San Antonio, TX
15. Brown E.G., Wood L., and Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 20 (1999) 109-117
16. Fisher L., Dixon D., Herson J., Frankowski R., Hearron M., and Peace K. Intention-to-treat in clinical trials. In: KE P. (Ed). Statistical Issues in Drug Research and Development (1990), Marcel Dekker, New York
17. Weinfert K. Repeated measures analyses: ANOVA, MANOVA, HLM. In: Grimm L., and Yarnold P. (Eds). Reading and Understanding More Multivariate Statistics (2000), American Psychological Press, Washington, DC 317-362
18. Gueorguieva R., and Krystal J.H. Move over ANOVA: Progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 61 (2004) 310-317
19. Brown H., and Prescott R. Applied Mixed Models in Medicine (1999), John Wiley and Sons, New York
20. Rosenthal R., Rosnow R., and Rubin D.B. Contrasts and Effect Sizes in Behavioral Research (2000), Cambridge University Press, Cambridge, England
21. Sackett D., Richardson W., Rosenberg W., and Haynes B. Evidence-Based Medicine. 2nd ed. (2000), Churchill Livingstone, London
22. Hammad T.A., Laughren T.P., and Racoosin J.A. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 26 (2006) 203-207
23. Hammad T.A., Laughren T., and Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63 (2006) 332-339
24. Ginsburg G.S., and Grover R.L. Assessing and treating social phobia in children and adolescents. Pediatr Ann 34 (2005) 119-127
25. March J.S. Combining medication and psychosocial treatments: An evidence-based medicine approach. International Review of Psychiatry 14 (2002) 155-163